The Latin America, Middle East and Africa Protein A Resin Market would witness market growth of 9.4% CAGR during the forecast period (2022-2028).
Protein A is utilized in R&D and drug discovery for the healthcare businesses mainly for its high selectivity and specificity for human IgG, whose usage is to treat diseases such as cancer and autoimmune diseases. Moreover, it is utilized in the biopharma sector in the procedure of developing GMP-compliant biologics that are authorized for commercialization & clinical usage.
The market is growing due to the rise in the biopharmaceutical & biotechnology businesses in drug advancement procedures, increased expenditure in synthetic biology, and growing monoclonal antibodies research. Furthermore, there has been growth in the demand for protein-engineered goods utilized for therapeutics & vaccine improvement through the biopharmaceutical businesses, which has a positive influence on the international market and is one of the main propelling factors.
Brazil has the most significant healthcare sector in Latin America and spends 9.1% of its GDP on healthcare. In 2021, there were about 88,000 healthcare supplementary services, 532,645 hospital beds, 502,000 physicians, and 89,000 drug stores.. Besides medical treatment and diagnosis, the public facility offers free medicines for some incurable disorders and encourages national vaccination schemes, mainly concentrating on children as well as elderly. Protein A resins are used in treating cancers and other diseases which require the purification of monoclonal antibodies. In addition, many nations are adopting protein A resins to provide better healthcare facilities to their people. This would support the market expansion in LAMEA region.
The Brazil market dominated the LAMEA Protein A Resin Market by Country 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $31.3 million by 2028.The Argentina market is experiencing a CAGR of 10% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 9.1% during (2022 - 2028).
Based on Product Type, the market is segmented into Agarose-based, Glass/Silica-based and Organic Polymer-based. Based on End Use, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, Academic Research Institutes and Others. Based on Type, the market is segmented into Recombinant and Natural. Based on Application, the market is segmented into Antibody Purification and Immunoprecipitation. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include General Electric (GE) Co. (GE Healthcare), Repligen Corporation, PerkinElmer, Inc, Thermo Fisher Scientific, Inc., Merck Millipore (Merck Group), Genscript Biotech Corporation, Agilent Technologies, Inc., Abcam plc, and Novasep Holdings SAS (Azulis Capital).
Protein A is utilized in R&D and drug discovery for the healthcare businesses mainly for its high selectivity and specificity for human IgG, whose usage is to treat diseases such as cancer and autoimmune diseases. Moreover, it is utilized in the biopharma sector in the procedure of developing GMP-compliant biologics that are authorized for commercialization & clinical usage.
The market is growing due to the rise in the biopharmaceutical & biotechnology businesses in drug advancement procedures, increased expenditure in synthetic biology, and growing monoclonal antibodies research. Furthermore, there has been growth in the demand for protein-engineered goods utilized for therapeutics & vaccine improvement through the biopharmaceutical businesses, which has a positive influence on the international market and is one of the main propelling factors.
Brazil has the most significant healthcare sector in Latin America and spends 9.1% of its GDP on healthcare. In 2021, there were about 88,000 healthcare supplementary services, 532,645 hospital beds, 502,000 physicians, and 89,000 drug stores.. Besides medical treatment and diagnosis, the public facility offers free medicines for some incurable disorders and encourages national vaccination schemes, mainly concentrating on children as well as elderly. Protein A resins are used in treating cancers and other diseases which require the purification of monoclonal antibodies. In addition, many nations are adopting protein A resins to provide better healthcare facilities to their people. This would support the market expansion in LAMEA region.
The Brazil market dominated the LAMEA Protein A Resin Market by Country 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $31.3 million by 2028.The Argentina market is experiencing a CAGR of 10% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 9.1% during (2022 - 2028).
Based on Product Type, the market is segmented into Agarose-based, Glass/Silica-based and Organic Polymer-based. Based on End Use, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, Academic Research Institutes and Others. Based on Type, the market is segmented into Recombinant and Natural. Based on Application, the market is segmented into Antibody Purification and Immunoprecipitation. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include General Electric (GE) Co. (GE Healthcare), Repligen Corporation, PerkinElmer, Inc, Thermo Fisher Scientific, Inc., Merck Millipore (Merck Group), Genscript Biotech Corporation, Agilent Technologies, Inc., Abcam plc, and Novasep Holdings SAS (Azulis Capital).
Scope of the Study
Market Segments Covered in the Report:
By Product Type
- Agarose-based
- Glass/Silica-based
- Organic Polymer-based
By End Use
- Pharmaceutical & Biopharmaceutical Companies
- Academic Research Institutes
- Others
By Type
- Recombinant
- Natural
By Application
- Antibody Purification
- Immunoprecipitation
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- General Electric (GE) Co. (GE Healthcare)
- Repligen Corporation
- PerkinElmer, Inc
- Thermo Fisher Scientific, Inc
- Merck Millipore (Merck Group)
- Genscript Biotech Corporation
- Agilent Technologies, Inc
- Abcam plc
- Novasep Holdings SAS (Azulis Capital)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Protein A Resin Market, by Product Type
1.4.2 LAMEA Protein A Resin Market, by End Use
1.4.3 LAMEA Protein A Resin Market, by Type
1.4.4 LAMEA Protein A Resin Market, by Application
1.4.5 LAMEA Protein A Resin Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Protein A Resin Market
Chapter 4. LAMEA Protein A Resin Market by Product Type
4.1 LAMEA Agarose-based Market by Country
4.2 LAMEA Glass/Silica-based Market by Country
4.3 LAMEA Organic Polymer-based Market by Country
Chapter 5. LAMEA Protein A Resin Market by End-use
5.1 LAMEA Pharmaceutical & Biopharmaceutical Companies Market by Country
5.2 LAMEA Academic Research Institutes Market by Country
5.3 LAMEA Others Market by Country
Chapter 6. LAMEA Protein A Resin Market by Type
6.1 LAMEA Recombinant Market by Country
6.2 LAMEA Natural Market by Country
Chapter 7. LAMEA Protein A Resin Market by Application
7.1 LAMEA Antibody Purification Market by Country
7.2 LAMEA Immunoprecipitation Market by Country
Chapter 8. LAMEA Protein A Resin Market by Country
8.1 Brazil Protein A Resin Market
8.1.1 Brazil Protein A Resin Market by Product Type
8.1.2 Brazil Protein A Resin Market by End-use
8.1.3 Brazil Protein A Resin Market by Type
8.1.4 Brazil Protein A Resin Market by Application
8.2 Argentina Protein A Resin Market
8.2.1 Argentina Protein A Resin Market by Product Type
8.2.2 Argentina Protein A Resin Market by End-use
8.2.3 Argentina Protein A Resin Market by Type
8.2.4 Argentina Protein A Resin Market by Application
8.3 UAE Protein A Resin Market
8.3.1 UAE Protein A Resin Market by Product Type
8.3.2 UAE Protein A Resin Market by End-use
8.3.3 UAE Protein A Resin Market by Type
8.3.4 UAE Protein A Resin Market by Application
8.4 Saudi Arabia Protein A Resin Market
8.4.1 Saudi Arabia Protein A Resin Market by Product Type
8.4.2 Saudi Arabia Protein A Resin Market by End-use
8.4.3 Saudi Arabia Protein A Resin Market by Type
8.4.4 Saudi Arabia Protein A Resin Market by Application
8.5 South Africa Protein A Resin Market
8.5.1 South Africa Protein A Resin Market by Product Type
8.5.2 South Africa Protein A Resin Market by End-use
8.5.3 South Africa Protein A Resin Market by Type
8.5.4 South Africa Protein A Resin Market by Application
8.6 Nigeria Protein A Resin Market
8.6.1 Nigeria Protein A Resin Market by Product Type
8.6.2 Nigeria Protein A Resin Market by End-use
8.6.3 Nigeria Protein A Resin Market by Type
8.6.4 Nigeria Protein A Resin Market by Application
8.7 Rest of LAMEA Protein A Resin Market
8.7.1 Rest of LAMEA Protein A Resin Market by Product Type
8.7.2 Rest of LAMEA Protein A Resin Market by End-use
8.7.3 Rest of LAMEA Protein A Resin Market by Type
8.7.4 Rest of LAMEA Protein A Resin Market by Application
Chapter 9. Company Profiles
9.1 General Electric (GE) Co. (GE Healthcare)
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 SWOT Analysis
9.2 Repligen Corporation
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments:
9.2.5.1 Partnerships, Collaborations, and Agreements:
9.2.5.2 Acquisition and Mergers:
9.3 PerkinElmer, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Acquisition and Mergers:
9.4 Thermo Fisher Scientific, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.5 Bio-Rad Laboratories, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expenses
9.5.5 Recent strategies and developments:
9.5.5.1 Product Launches and Product Expansions:
9.6 Merck Millipore (Merck Group)
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expense
9.7 Genscript Biotech Corporation
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional & Segmental Analysis
9.7.4 Research & Development Expenses
9.8 Agilent Technologies, Inc.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.9 Abcam plc
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expenses
9.10. Novasep Holdings SAS (Azulis Capital)
9.10.1 Company Overview
Companies Mentioned
- General Electric (GE) Co. (GE Healthcare)
- Repligen Corporation
- PerkinElmer, Inc
- Thermo Fisher Scientific, Inc.
- Merck Millipore (Merck Group)
- Genscript Biotech Corporation
- Agilent Technologies, Inc.
- Abcam plc
- Novasep Holdings SAS (Azulis Capital)
Methodology
LOADING...
